Ken Griffin Spero Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Spero Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 500 shares of SPRO stock, worth $665. This represents 0.0% of its overall portfolio holdings.

Number of Shares

500

Holding current value

$665

% of portfolio

0.0%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$1.27 - $1.8 $396,283 - $561,661	312,034 New	312,034 $405,000
Q4 2023 Feb 14, 2024	BUY	$1.0 - $1.47 $32,274 - $47,442	32,274 New	32,274 $47,000
Q2 2023 Aug 14, 2023	BUY	$1.42 - $1.95 $21,237 - $29,164	14,956 New	14,956 $21,000
Q2 2022 Aug 15, 2022	BUY	$0.74 - $7.44 $72,189 - $725,801	97,554 Added 903.53%	108,351 $80,000
Q1 2022 May 16, 2022	SELL	$7.87 - $15.15 $7,988 - $15,377	-1,015 Reduced 8.59%	10,797 $94,000
Q2 2021 Aug 16, 2021	SELL	$12.22 - $15.79 $101,034 - $130,551	-8,268 Reduced 41.18%	11,812 $164,000
Q1 2021 May 17, 2021	SELL	$13.23 - $21.48 $166,142 - $269,745	-12,558 Reduced 38.48%	20,080 $296,000
Q4 2020 Feb 16, 2021	BUY	$11.65 - $22.07 $131,971 - $250,008	11,328 Added 53.16%	32,638 $633,000
Q3 2020 Nov 16, 2020	BUY	$8.96 - $14.12 $190,937 - $300,897	21,310 New	21,310 $238,000

Others Institutions Holding SPRO

# of Institutions

Shares Held

15.5M

Call Options Held

500

Put Options Held

Anson Funds Management LP Dallas, TX

3.75M
Shares

$4.99 Million
0.74% of portfolio
Vanguard Group Inc Valley Forge, PA

1.77M
Shares

$2.35 Million
0.0% of portfolio
Atlas Venture Associates Ix, LLC Boston, MA

1.35M
Shares

$1.8 Million
14.54% of portfolio
Acadian Asset Management LLC Boston, MA

1.07M
Shares

$1.43 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

976K
Shares

$1.3 Million
0.0% of portfolio

View Full List

About Spero Therapeutics, Inc.

Ticker SPRO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,067,500
Market Cap $46.6M
Description
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...

More about SPRO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account